Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 7/20 | 0.57 |
| ▸ | NSD2 | O96028 | 3/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25037735 | 0.91 | SETD2 (0.58) | SETD2NSD2CNR1ABL1 | |
| SCHEMBL25040178 | 0.90 | SETD2 (0.59) | SETD2NSD2CNR1CYP11B1CYP11B2 | |
| SCHEMBL25039829 | 0.86 | SETD2 (0.63) | SETD2NSD2 | |
| SCHEMBL25040762 | 0.85 | SETD2 (0.59) | SETD2NSD2 | |
| SCHEMBL26099837 | 0.85 | SETD2 (0.56) | SETD2NSD2 | |
| SCHEMBL25039743 | 0.83 | SETD2 (0.56) | SETD2NSD2BRAFBRD4CREBBP | |
| SCHEMBL25040301 | 0.83 | SETD2 (0.56) | SETD2NSD2CNR1 | |
| SCHEMBL25040666 | 0.83 | SETD2 (0.58) | SETD2NSD2 | |
| SCHEMBL26099626 | 0.83 | SETD2 (0.56) | SETD2NSD2 | |
| SCHEMBL26098486 | 0.82 | SETD2 (0.55) | SETD2NSD2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SETD2 1/4885NSD2 35/4885CNR1 4145/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | SETD2 8/4885NSD2 6/4885CNR1 4508/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SETD2 3/4885NSD2 14/4885CNR1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.